CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Injection - Colony Stimulating Factors codes

14 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 11.54M services · est. ▲ 15.2% YoY · 4,081 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5.69M observed fee-for-service services

See the national market for Q5110 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 4.02M services · est. ▼ 67.6% YoY · 1,257 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.87M observed fee-for-service services

See the national market for Q5101 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1449 Injection, eflapegrastim-xnst, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 3.25M services · est. ▲ 160.1% YoY · 6,076 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.73M observed fee-for-service services

See the national market for J1449 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 1.47M services · est. ▼ 6.9% YoY · 543 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 691,908 observed fee-for-service services

See the national market for J1442 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 194,074 services · est. ▲ 599.9% YoY · 3,426 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 96,798 observed fee-for-service services

See the national market for Q5127 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 193,323 services · est. ▲ 97.1% YoY · 3,699 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 97,926 observed fee-for-service services

See the national market for Q5108 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1447 Injection, tbo-filgrastim, 1 microgram CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 174,769 services · est. ▲ 11.5% YoY · 75 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 88,741 observed fee-for-service services

See the national market for J1447 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 145,046 services · est. ▲ 11.9% YoY · 2,994 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 76,981 observed fee-for-service services

See the national market for Q5111 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2505 Injection, pegfilgrastim, 6 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 93,218 services · est. ▼ 28.0% YoY · 22,471 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 53,626 observed fee-for-service services

See the national market for J2505 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2506 Injection, pegfilgrastim, excludes biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 81,196 services · est. ▼ 84.2% YoY · 1,830 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 41,891 observed fee-for-service services

See the national market for J2506 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5130 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 64,998 services · est. · 1,048 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 34,323 observed fee-for-service services

See the national market for Q5130 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5122 Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 40,918 services · est. ▼ 81.3% YoY · 993 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 21,968 observed fee-for-service services

See the national market for Q5122 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2820 Injection, sargramostim (gm-csf), 50 mcg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 8,545 services · est. ▼ 56.9% YoY · 16 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,262 observed fee-for-service services

See the national market for J2820 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5120 Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 3,919 services · est. ▼ 97.2% YoY · 124 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 1,908 observed fee-for-service services

See the national market for Q5120 → ranked groups · states · 12-yr trend